INSTAGE (TM) : A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment

Trial Profile

INSTAGE (TM) : A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Nintedanib (Primary) ; Sildenafil
  • Indications Idiopathic pulmonary fibrosis; Lung disorders
  • Focus Therapeutic Use
  • Acronyms INSTAGE; INSTAGE (TM)
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Nov 2017 Planned End Date changed from 15 Mar 2018 to 19 Apr 2018.
    • 17 Oct 2017 Planned End Date changed from 14 May 2018 to 15 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top